224 related articles for article (PubMed ID: 27401997)
1. Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.
Keating GM
Drugs; 2016 Aug; 76(12):1203-11. PubMed ID: 27401997
[TBL] [Abstract][Full Text] [Related]
2. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
3. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
[TBL] [Abstract][Full Text] [Related]
4. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
5. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
7. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
8. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
9. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
Waked I; Esmat G; Fouad R; Allam N; Hassany M; Mohey M; Shiha G; Soliman R; Qaqish RB; Hall C; Alami NN; Kopecky-Bromberg S; Mobashery N
J Med Virol; 2018 Nov; 90(11):1739-1744. PubMed ID: 29900553
[TBL] [Abstract][Full Text] [Related]
10. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED
Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
[TBL] [Abstract][Full Text] [Related]
11. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Schnell G; Tripathi R; Krishnan P; Beyer J; Reisch T; Irvin M; Dekhtyar T; Setze C; Rodrigues L; Alves K; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
J Med Virol; 2018 Jan; 90(1):109-119. PubMed ID: 28842997
[TBL] [Abstract][Full Text] [Related]
12. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
[TBL] [Abstract][Full Text] [Related]
13. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
14. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.
Miyasaka A; Yoshida Y; Yoshida T; Murakami A; Abe K; Ohuchi K; Kawakami T; Watanabe D; Hoshino T; Sawara K; Takikawa Y
Intern Med; 2018 Oct; 57(19):2807-2812. PubMed ID: 29780135
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
[TBL] [Abstract][Full Text] [Related]
16. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
[TBL] [Abstract][Full Text] [Related]
17. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
[TBL] [Abstract][Full Text] [Related]
18. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Shiffman ML; Rustgi V; Bennett M; Forns X; Asselah T; Planas Vila R; Liu L; Pedrosa M; Moller J; Reau N
Am J Gastroenterol; 2016 Jun; 111(6):845-51. PubMed ID: 27045929
[TBL] [Abstract][Full Text] [Related]
20. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]